Podcast of business and financial stories, Behind the Money

Behind the Money

Podcast of business and financial stories

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the business and financial stories of the moment with reporting from Financial Times journalists around the world.

Equity Bottom-Up

<ul><li>Pfizer CEO Albert Borla receives a strange email from the company's former CFO Frank D'Amelio, signaling the beginning of a chaotic activist investor campaign</li><li>Pfizer's success with the Covid-19 vaccine leads to record highs in market cap, but challenges arise as the vaccine becomes old news and competitors emerge in the weight loss drug sector</li><li>Pfizer's acquisition of cancer drug maker CGenta for $43 billion is criticized by investors, leading to a collapse in the company's share price and making it a prime target for an activist investor</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.</em></p>

Pfizer CEO Albert Borla receives a strange email from the company's former CFO Frank D'Amelio, signaling the beginning of a chaotic activist investor campaignPfizer's success with the Covid-19 vaccine leads to record highs in market cap, but challenges arise as the vaccine becomes old news and competitors emerge in the weight loss drug sectorPfizer's acquisition of cancer drug maker CGenta for $43 billion is criticized by investors, leading to a collapse in the company's share price and making it a prime target for an activist investorThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

An activist tried to take on Pfizer. Then things got messy

United States

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pfizer (PFE UN)

An activist tried to take on Pfizer. Then things got messy

Pfizer, a pharmaceutical giant, faces challenges post-pandemic including a failed acquisition and investor doubts about its future growth potential.

Behind the Money

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)